| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.48.11.4453-4456.2004 |
| P8608 | Fatcat ID | release_hfm2cyuufnb3bbsr4id4uhncei |
| P932 | PMC publication ID | 525414 |
| P698 | PubMed publication ID | 15504881 |
| P50 | author | Giovanni Di Bonaventura | Q42800767 |
| P2093 | author name string | Raffaele Piccolomini | |
| Carla Picciani | |||
| Domenico D'Antonio | |||
| Ilaria Spedicato | |||
| P2860 | cites work | Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. | Q30452376 |
| New and emerging yeast pathogens | Q30452880 | ||
| Organism-dependent fungicidal activities of azoles | Q33702101 | ||
| Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans | Q33979304 | ||
| Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. | Q34105231 | ||
| New automated method for determining postantifungal effect of amphotericin B against Candida species: effects of concentration, exposure time, and area under the curve | Q34253294 | ||
| Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance | Q34641319 | ||
| In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. | Q34749162 | ||
| Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood | Q34774859 | ||
| Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. | Q35136891 | ||
| Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. | Q36242539 | ||
| Mycoses caused by Candida lusitaniae. | Q39681816 | ||
| In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. | Q39731811 | ||
| Caspofungin activity against clinical isolates of fluconazole-resistant Candida | Q40404311 | ||
| Antifungal resistance in non- albicans Candida species | Q40691585 | ||
| Therapeutic drug monitoring of systemic antifungal therapy | Q41700394 | ||
| Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. | Q44755047 | ||
| Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents | Q44764319 | ||
| In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents | Q44769635 | ||
| Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia | Q48693586 | ||
| Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii | Q70047840 | ||
| The postantibiotic effect of antifungal agents against common pathogenic yeasts | Q72807287 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluconazole | Q411478 |
| amphotericin B | Q412223 | ||
| voriconazole | Q412236 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 4453-4456 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies | |
| P478 | volume | 48 |
| Q40799658 | Antifungal therapies in murine infections by Candida kefyr |
| Q84765624 | Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei |
| Q42363545 | Caspofungin affects growth of Paracoccidioides brasiliensis in both morphological phases. |
| Q38586680 | Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes |
| Q41473569 | Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments |
| Q37718385 | Echinocandin pharmacodynamics: review and clinical implications. |
| Q42549201 | Effects of caspofungin against Candida guilliermondii and Candida parapsilosis |
| Q42111926 | Five-minute exposure to caspofungin results in prolonged postantifungal effects and eliminates the paradoxical growth of Candida albicans |
| Q42110115 | Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii |
| Q42834137 | In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinical isolates of Candida spp |
| Q47835566 | In vitro antifungal susceptibility patterns of planktonic and sessile Candida kefyr clinical isolates |
| Q39196802 | Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use. |
| Q34960317 | Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections |
| Q36140647 | Liposomal amphotericin B: clinical experience and perspectives |
| Q42432990 | Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography |
| Q37624716 | Pharmacological properties of antifungal drugs with a focus on anidulafungin |
| Q47434555 | Postantifungal effect of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates |
| Q40491629 | Sensitivity of Candida albicans to essential oils: are they an alternative to antifungal agents? |
| Q37159301 | Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV(+) patients to fluconazole, amphotericin B and Caspofungin. killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolate |
| Q33719218 | Synthesis, characterization, and in vitro activity against Candida spp. of fluconazole encapsulated on cationic and conventional nanoparticles of poly(lactic-co-glycolic acid) |
| Q39619972 | The postantifungal and paradoxical effects of echinocandins against Candida spp. |
| Q37846260 | Treatment of candidemia in adult patients without neutropenia--an inconvenient truth |
| Q36729599 | Voriconazole : a review of its use in the management of invasive fungal infections |
| Q37805648 | What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast |
Search more.